199 results about "Retinal" patented technology

The invention belongs to the technical field of biological medicine, and discloses an application of CDH5 protein and / or SELL protein as a biomarker in preparation of a kit for detecting diabetic retinopathy, the biomarker comprises at least one of CDH5 protein and SELL protein; the amino acid sequence of the CDH5 protein is as shown in SEQ NO: 1, and the amino acid sequence of the SELL protein is as shown in SEQ NO: 2. The CDH5 protein and / or the SELL protein are / is used as the biomarker for detecting diabetic retinopathy, especially for detecting early diabetic retinopathy, good sensitivity and specificity can be obtained, the accuracy of a detection result is ensured, early diagnosis and early treatment are realized, sampling is convenient and non-invasive, and large-scale popularization can be realized.

A trace element supplement consisting of lutein, zeaxanthin, astaxanthin, anthocyanins, and proanthocyanidins is designed to improve retinal health in children and adolescents, relieve eye strain, and slow the progression of myopia. The daily dose is 1–20 mg lutein, 0.2–4 mg zeaxanthin, 0.5–8 mg astaxanthin, 10–700 mg taurine, and 0.5–8.5 mg zinc; the nighttime dose is 1–100 mg eyebright extract, 10–300 mg chamomile extract, 1–200 mg anthocyanins, and 1–500 mg proanthocyanidins.

The invention relates to gene therapy of ocular conditions. Described herein are compositions and methods for delivering therapeutic products, such as therapeutic proteins (e.g., antibodies), therapeutic RNAs (e.g., shRNAs, siRNAs, and miRNAs), and therapeutic aptamers, to the retinal / vitreous humor of the eye of a human subject to treat ocular conditions, involving, for example, recombinant viral vectors, such as recombinant adeno-associated virus (rAAV) vectors.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present invention discloses a β-carotene-grape seed extract eye-care preparation for retinal protection, relating to functional health foods. The preparation comprises active components and food-acceptable excipients. In parts by weight, the active components include 1–4 parts lutein, 0.5 –2 parts meso-zeaxanthin, 2 – 6 parts β-carotene, 8 – 25 parts blueberry extract, 5 – 18 parts grape seed extract, 0.2–1 part L-ergothioneine, 0.5–3 parts saffron extract, and 1–5 parts phosphatidylserine. The excipients comprise a filler, disintegrant, binder, and lubricant, with a weight ratio of active components to excipients of 1:1 to 1:4. By combining these eight components at specific ratios, the invention achieves synergistic effects, protects retinal health, and reduces blue-light damage. Dual-phase microencapsulation based on solubility, together with standardized preparation steps, improves stability and utilization efficiency.

The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an αv integrin, such as diabetic retinopathy.

The utility model provides a retina injector. The retina injector comprises a liquid injection body, an injection needle, a piston and an administration dosage control structure. The liquid injection body is provided with a hollow cavity used for containing liquid, a liquid injection opening and a material pushing opening, the liquid injection opening is communicated with the cavity and used for injecting the liquid into the cavity, and the material pushing opening is formed in one end of the cavity and communicated with the cavity. The injection needle is connected to one end of the liquid injection body. The piston is arranged in the cavity in a sliding mode through the material pushing opening. The administration dosage control structure is arranged in a mounting groove in the liquid injection body and is sealed with the mounting groove. The administration dosage control structure comprises a fixing assembly, a cover plate, a first material blocking part and a second material blocking part, the first material blocking part and the second material blocking part are both connected to the cover plate, the cover plate is movably connected to the fixing assembly, and the first material blocking part and the second material blocking part are of a linkage structure which ascends and descends in the cavity. The cover plate is operated so that the first material blocking piece or the second material blocking piece can movably stretch into the cavity to prevent the piston from sliding forwards.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

This invention relates to the field of traditional Chinese medicine (TCM) technology. The invention provides a TCM composition for treating glaucoma and its preparation method, comprising the following components in parts by weight: 18-28 parts of Cassia seed, 12-18 parts of Lycium fruit, 12-18 parts of Eriocaulon buergerianum, 10-15 parts of vinegar-processed Cyperus rotundus, 10-15 parts of mulberry leaf, 10-15 parts of Ligusticum chuanxiong, 8-12 parts of Polyporus umbellatus, 5-8 parts of Pueraria lobata, 5-8 parts of Akebia quinata, 3-5 parts of Curcuma longa, 3-5 parts of Indigo naturalis, and 2-4 parts of prepared licorice root. The TCM composition of this invention has a strong effect in lowering intraocular pressure, improving retinal blood supply, and preventing optic nerve atrophy caused by glaucoma; simultaneously, the processing method maximizes the retention of the active pharmaceutical ingredients. Furthermore, the technical solution of this invention achieves a dual improvement in efficacy and safety, and also reduces the recurrence rate and side effects.

The present invention provides methods for treating or preventing diabetic retinopathy. e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include administering 2 mg of aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and an 8-week interval (2q16). In addition. the present invention provides methods for reversing or halting the progression of NPDR to PDR (e.g., such that NPDR is reduced by 2 or 3 levels) or preventing the occurrence or recurrence of a vision-threatening complication by administering aflibercept according to the dosage regimens presented herein.

The application discloses a preparation method and application of a paeonol derivative, and relates to the technical field of biomedicine. The paeonol derivative has the chemical structure as shown in the following formula: or. The paeonol extraction preparation method is simple, and the extraction rate of the paeonol is high. The prepared paeonol derivative has more excellent antioxidant activity, and the anti-inflammatory effect is enhanced, the anti-platelet aggregation effect is better, and the paeonol derivative also has good inhibitory activity on the occurrence and development of diabetic retinopathy.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

Provided are sequence variants and fusion proteins of the photosensitive ion channel protein ChRmine and their use in treating retinal neurodegenerative diseases. These ChRmine variants and fusion proteins exhibit improved protein properties and enhanced photoresponsive characteristics compared with the wildtype ChRmine, therefore may provide effective optogenetic tools to improve the therapeutic treatment of the retinal neurodegenerative diseases.

The present invention relates to the to the field of pharmaceutical compositions for ocular diseases, in particular, retinal neurogenerative diseases. The invention provides pharmaceutical compositions to be applied topically in the eyes, including peptides and methods for preparing them thereof. This invention further relates to ophthalmic pharmaceutical composition for use in the topical eye treatment and / or prevention of a retinal neurodegenerative disease.

Provided are an expression cassette for AAV gene therapy of a neovascular ophthalmic disease, a plasmid for producing rAAV including the expression cassette, an rAAV produced by the plasmid, and use of the rAAV. By the expression cassette and the plasmid according to aspects, rAAV virus particles having reduced immunogenicity can be produced with high productivity and high quality, and an rAAV thus produced can reach a therapeutic concentration of aflibercept in the retina even at a low viral dose, thereby minimizing capsid-induced immune responses.

The invention relates to the field of biological medicine, in particular to a retina organ with a vision improving function and a preparation method and application thereof. According to the method, the bottleneck in the prior art is broken through through innovative integration of low-intensity ultrasonic stimulation and a retina organoid technology, the advantages of efficiently accelerating differentiation and maturation of the photoreceptor and improving the differentiation efficiency of the photoreceptor are achieved, meanwhile, the bottleneck of transplantation integration is broken through, survival and integration of the graft are improved, and the purpose of recovering vision is achieved. In conclusion, the retina organoid culture method capable of promoting differentiation of the photoreceptor through ultrasonic stimulation is constructed for the first time, and a new view angle can be provided for research on treatment of retina degenerative diseases. Meanwhile, the core bottlenecks of insufficient photoreceptor differentiation and low transplantation integration rate of the retinal organ are solved, the retinal organ subjected to low-intensity ultrasonic stimulation can be used as a high-quality graft source, and a novel treatment strategy is provided for retinal degenerative diseases.

The invention provides a biomarker for detecting anti-VEGF treatment typing of diabetic macular edema and extracellular vesicle protein for judging the severity of diabetic retinopathy, and the protein with remarkable expression difference is screened out by analyzing the expression difference of the extracellular vesicle protein in aqueous humor of a patient. Wherein C5 and CD34 can be used as biomarkers of DME anti-VEGF treatment typing, C5 can be used for judging the severity of diabetic retinopathy (DR), important guidance is provided for DME or DR personalized treatment, and the C5 and CD34 have wide clinical application prospects.

The invention relates to a novel medical application of cinobufagin, and the cinobufagin is used as an N-myc protein inhibition / degradation agent and can be used for anti-tumor treatment of neuroblastoma and retinoblastoma.

To provide a nucleic acid molecule, and the like for targeting CYP4 V2 gene.SOLUTION: There are provided in the present disclosure: a nucleic acid molecule (e.g., sgRNA or gRNA molecule) for targeting CYP4 V2 gene encoding cytochrome P450, family 4, subfamily V, polypeptide 2 protein; and a donor nucleic acid molecule specific for CYP4 V2 gene. Additionally, there are provided the uses thereof for targeting, disrupting human CYP4 V2 gene, and / or correcting mutations (e.g., c.802-8_810del17insGC mutation) and for treating Bietti's crystalline retinopathy (BCD).SELECTED DRAWING: None

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist, with an optimized GLP-1R agonist / FGF21 compound activity ratio. The present invention also relates to the use of said combinations, pharmaceutical compositions and fusion molecules as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.

Disclosed are methods for assessing the presence or absence of a therapeutic concentration of a deuterated docosahexaenoic acid during treatment of a patient with a retinal oxidative disease.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The present invention provides a novel variant AAV capsid protein, a recombinant adeno-associated virus (rAAV) virion comprising same, and a pharmaceutical composition for the prevention or treatment of retinal or liver disease, comprising the rAAV virion.

Provided are methods for treating an ocular neovascular disease in an individual by reducing Auction of central subfoveal thickness (CST) or central retinal thickness (CRT), comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and Ranked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.

The invention relates to the field of biological medicine and ophthalmic diseases, in particular to a target protein inhibitor for preventing and treating proliferative diabetic retinopathy and a screening method and application of the target protein inhibitor. The screening method comprises the following steps: 1) obtaining a three-dimensional crystal structure of CTSH; 2) constructing a binding pocket at an active site; 3) performing molecular docking and scoring on the small molecule library, and screening candidate compounds with binding energy lower than a preset threshold value; and 4) performing molecular dynamics simulation on the candidate compound and the CTSH compound, and selecting a compound with a stable structure and low binding free energy as an inhibitor. The inhibitor obtained by screening comprises eriodictyin, polygala tenuifolia sucrose ester B or an AP-III-a4 inhibitor. Genetic causal inference proves that CTSH has a causal driving effect on PDR, inflammation and pathological angiogenesis can be remarkably inhibited by regulating CTSH expression under a high glucose condition, and effective inhibitor components are finally screened.

The application provides a granulocyte-guided double-space semantic calibration clustering method for diabetic retinopathy, comprising the following steps: step 1, designing an independent encoder to extract view-specific features; step 2, performing view quality evaluation on the view-specific embedding features output by each independent encoder, and calculating the confidence weight of each view; step 3, realizing double-space collaborative semantic calibration in the feature space and the clustering space; step 4, dividing the lesion semantic unit of diabetic retinopathy through granulocyte pre-modeling, and screening an initial clustering center from high-confidence granulocytes; and step 5, dynamically adjusting the exploration, utilization strategy and clustering center update step length based on the granulocyte confidence, and combining the semantic calibration signal to realize adaptive clustering optimization. The method helps to improve the accuracy and consistency of the double-view image staging clustering of diabetic retinopathy, and significantly reduces the early lesion missed diagnosis rate and the medium-term staging confusion rate.